In the company’s news yesterday,
IDM Pharma Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) released a positive review of IDM’s L-MTP-PuE, or MEPACT, to treat resectable osteosarcoma. The committee also recommended that IDM receive authorization for centralized marketing of L-MTP-PuE in Europe through the European Commission. The company anticipates approval in early 2009.
Timothy P. Walbert, president and CEO of IDM, said the positive opinion will help IDM launch L-MTP-PuE into the market, benefiting the company as well as cancer patients and their families.
“The recommendation for approval by the CHMP is a great victory for many young patients and their families and is a significant step for the company in bringing this important treatment to market,” Walbert stated in the press release. “The committee’s decision validates the clinical trial data and the belief of investigators, patients and IDM Pharma that L-MTP-PE provides a significant overall survival benefit for osteosarcoma patients and meets a significant unmet treatment need.”
Centralized marketing authorization will allow for the exclusive marketing of L-MTP-PuE for 10 years in the 27 Member States of the European Union, as well as in Iceland, Liechtenstein and Norway. This will mark the first approved new treatment for osteosarcoma in more than 20 years.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
